Novartis Gene Therapies (formerly AveXis) is rethinking medicine to improve and extend the lives of people with rare genetic diseases such as spinal muscular atrophy. comm:unications has been active in all areas of communications for Novartis Gene Therapies since 2020. In this particularly sensitive area, a great deal of tact and PR expertise is required to communicate in a measured and targeted manner, while adhering to the strictest compliance rules. The activities of comm:unications’ pharmaceutical PR experts include strategic consulting, the media-friendly preparation of sensitive and complex content, the conception of press conferences and the preparation of media appearances, including media training. The agency’s sustainable approach has set an example for other markets in Europe. comm:unications has been a “Preferred Partner” of Novartis Austria since 2024. Benefit from our expertise and contact us!